Clinical Trial Update: Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy [Phase 3]

View source ↗

Summary

This Phase 3 safety study investigates adding Everolimus to adjuvant hormone therapy in women with ER-positive, HER2-negative primary breast cancer who are dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: UNICANCER | Conditions: Primary Non-metastatic Breast Cancer, Who Remain Disease-free | Phase 3 | Status: ACTIVE_NOT_RECRUITING